Enhanced External Counterpulsation on Delayed Onset Muscle Soreness

Effects of Enhanced External Counterpulsation on Delayed Onset Muscle Soreness, a Pilot Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02175316

Enrollment

Registered

2014-06-26

Start date

2014-04-30

Completion date

2017-09-06

Last updated

2020-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Tightness

Brief summary

This study will evaluate the effects of Enhanced External Counterpulsation on delayed onset muscle soreness. The primary outcomes will be duration of delayed onset muscle soreness, WBC count, CRP count, CPK count, and pain tolerance.

Interventions

DEVICEEnhanced External Counterpulsation

Enhanced External Counterpulsation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 59 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy active Duty or DoD beneficiaries between 25 and 59 years old

Exclusion criteria

* Not on a physical profile * Not taking any OTC or prescription pain medications or workout supplements

Design outcomes

Primary

Measure	Time frame	Description
Change in delayed onset muscle soreness over time.	At 3, 6, 9, 12, 15, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 Hours	Likert pain surveys

Secondary

Measure	Time frame	Description
Pain tolerance	Baseline, 24 hours, 2 days 3 days 4 days 33 days	Pain tolerance measured by mmHg pressure required to elicit a delayed-onset muscle pain response.
Bio-markers for muscle inflammation	Baseline, 24 hours, 2 days 3 days 4 days 33 days	Bio-markers for muscle inflammation: C-reactive protein, creatine phosphokinase, and white blood cell count.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026